StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research note released on Sunday. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Trading Up 74.1 %
Shares of PULM opened at $3.57 on Friday. The stock’s 50 day moving average is $2.10 and its two-hundred day moving average is $2.04. Pulmatrix has a twelve month low of $1.55 and a twelve month high of $4.12. The firm has a market capitalization of $13.04 million, a PE ratio of -1.35 and a beta of 0.99.
Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share for the quarter. The business had revenue of $1.55 million during the quarter. Pulmatrix had a negative net margin of 96.51% and a negative return on equity of 45.97%.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- What is a buyback in stocks? A comprehensive guide for investors
- Rocket Lab is the Right Stock for the Right Time
- There Are Different Types of Stock To Invest In
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- How to Capture the Benefits of Dividend Increases
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
